Invention Grant
- Patent Title: Process for preparing amorphous rosuvastatin calcium of impurities
- Patent Title (中): 制备无定形罗苏伐他汀钙杂质的方法
-
Application No.: US11922532Application Date: 2006-06-22
-
Publication No.: US09150518B2Publication Date: 2015-10-06
- Inventor: Marko Zlicar , Zdenko Casar
- Applicant: Marko Zlicar , Zdenko Casar
- Applicant Address: unknown Slovenia
- Assignee: Lek Pharmaceuticals, D.D.
- Current Assignee: Lek Pharmaceuticals, D.D.
- Current Assignee Address: unknown Slovenia
- Agency: Luedeka Neely Group, P.C.
- Priority: SIP200500188 20050624
- International Application: PCT/EP2006/006007 WO 20060622
- International Announcement: WO2006/136407 WO 20061228
- Main IPC: C07D239/42
- IPC: C07D239/42

Abstract:
A pure amorphous form of rosuvastatin calcium substantially free from alkali metal impurities is disclosed. A process of preparing a pure amorphous form of rosuvastatin calcium is disclosed, which comprises hydrolysis of C1-C5 alkyl esters of rosuvastatin, preferably tert-butyl ester of rosuvastatin, with an organic nitrogen base, e.g. guanidines, amidines, amines and quaternary ammonium hydroxides, in the presence of water, optionally containing aprotic solvent, following the conversion of thus obtained rosuvastatin salt with a source of calcium to obtain rosuvastatin calcium, which is then isolated. An alternative process is disclosed, which comprises the conversion of numerous novel ammonium salts of rosuvastatin, preferably tert-octylammonium salt of rosuvastatin, with the source of calcium to desired commercial rosuvastatin calcium. Rosuvastatin calcium is an inhibitor of HMG CoA reductase, useful in the treatment of hyperlipidemia, hypercholesterolemia and atherosclerosis.
Public/Granted literature
- US20090111839A1 Process for Preparing Amorphous Rosuvastatin Calcium of Impurities Public/Granted day:2009-04-30
Information query